Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.

Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny DF, Reddy SA, Vado KP, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, Venhaus RR, Momtaz P, Shoushtari AN, Callahan MK, Chapman PB, Wolchok JD, Subrahmanyam PB, Maecker HT, Panageas KS, Barker CA.

Clin Cancer Res. 2020 Mar 23. pii: clincanres.3936.2019. doi: 10.1158/1078-0432.CCR-19-3936. [Epub ahead of print]

PMID:
32205463
2.

The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease.

Applebaum AJ, Polacek LC, Walsh L, Reiner AS, Lynch K, Benvengo S, Buthorn J, Atkinson TM, Mao JJ, Panageas KS, Diamond EL.

Leuk Lymphoma. 2020 Feb 24:1-12. doi: 10.1080/10428194.2020.1719090. [Epub ahead of print]

PMID:
32090658
3.

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.

Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, Postow MA, Chapman PB.

J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464. [Epub ahead of print]

PMID:
32053428
4.

Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.

Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Yabe M, Petrova-Drus K, Panageas KS, Reiner A, Rosenblum M, Diamond EL.

Neuro Oncol. 2020 Jan 17. pii: noaa008. doi: 10.1093/neuonc/noaa008. [Epub ahead of print]

PMID:
31950179
5.

Assessment of variation in 30-day mortality following cancer surgeries among older adults across US hospitals.

Lipitz-Snyderman A, Lavery JA, Bach PB, Li DG, Yang A, Strong VE, Russo A, Panageas KS.

Cancer Med. 2020 Mar;9(5):1648-1660. doi: 10.1002/cam4.2800. Epub 2020 Jan 9.

6.

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.

Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE.

Ann Surg Oncol. 2020 Apr;27(4):1180-1188. doi: 10.1245/s10434-019-08099-9. Epub 2019 Dec 17.

PMID:
31848819
7.

Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.

Schaff LR, Yan D, Thyparambil S, Tian Y, Cecchi F, Rosenblum M, Reiner AS, Panageas KS, Hembrough T, Lin AL.

J Neurooncol. 2020 Jan;146(1):163-170. doi: 10.1007/s11060-019-03358-x. Epub 2019 Dec 10.

PMID:
31823165
8.

High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.

Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, Coit DG, Ariyan CE.

Cancer. 2020 Jan 1;126(1):76-85. doi: 10.1002/cncr.32506. Epub 2019 Oct 4.

PMID:
31584709
9.

Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.

Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H.

J Exp Med. 2019 Dec 2;216(12):2701-2713. doi: 10.1084/jem.20190738. Epub 2019 Sep 19.

PMID:
31537643
10.

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.

Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD.

Melanoma Res. 2020 Feb;30(1):71-75. doi: 10.1097/CMR.0000000000000633.

PMID:
31425479
11.

Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.

Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A.

J Neurooncol. 2019 Sep;144(3):553-562. doi: 10.1007/s11060-019-03257-1. Epub 2019 Aug 3.

PMID:
31377920
12.

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.

Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, Gupta A, Harding JJ, Moral JA, Balachandran VP, Wolchok JD, Merghoub T.

J Clin Invest. 2019 Jul 22;129(8):3435-3447. doi: 10.1172/JCI128562. eCollection 2019 Jul 22.

13.

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB.

J Neurooncol. 2019 Sep;144(2):403-407. doi: 10.1007/s11060-019-03243-7. Epub 2019 Jul 19.

PMID:
31325145
14.

Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.

Lavery JA, Panageas KS.

J Hosp Manag Health Policy. 2019 Apr;3. pii: 8. doi: 10.21037/jhmhp.2019.04.01. Epub 2019 Apr 9. No abstract available.

15.

Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance.

Lavery JA, Lipitz-Snyderman A, Li DG, Bach PB, Panageas KS.

J Eval Clin Pract. 2020 Feb;26(1):66-71. doi: 10.1111/jep.13168. Epub 2019 May 9.

PMID:
31069903
16.

A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, Abdel-Wahab O, Rampal R, Janku F, Brewer K, Campbell J, Mao JJ, Atkinson TM, Panageas KS.

Blood Adv. 2019 Apr 9;3(7):934-938. doi: 10.1182/bloodadvances.2018030502.

17.

Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data.

Lavery JA, Lipitz-Snyderman A, Li DG, Bach PB, Panageas KS.

JCO Clin Cancer Inform. 2019 Feb;3:1-24. doi: 10.1200/CCI.18.00093.

18.

EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

Hovinga KE, McCrea HJ, Brennan C, Huse J, Zheng J, Esquenazi Y, Panageas KS, Tabar V.

J Neurooncol. 2019 Apr;142(2):337-345. doi: 10.1007/s11060-019-03102-5. Epub 2019 Jan 24.

19.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK.

Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

20.

An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.

Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S.

Nat Cell Biol. 2019 Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21.

21.

Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM.

Blood. 2019 Feb 21;133(8):781-789. doi: 10.1182/blood-2018-06-860874. Epub 2018 Dec 21.

22.

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.

Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.

23.

Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting.

Lipitz-Snyderman A, Atoria CL, Schleicher SM, Bach PB, Panageas KS.

J Oncol Pract. 2019 Jan;15(1):e30-e38. doi: 10.1200/JOP.18.00315. Epub 2018 Dec 13.

24.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. No abstract available.

25.

Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma".

Reiner AS, Goldman DA, Diamond EL, DeAngelis LM, Tabar V, Panageas KS.

World Neurosurg. 2018 Sep;117:466. doi: 10.1016/j.wneu.2018.04.156. No abstract available.

PMID:
30149428
26.

Design considerations for early-phase clinical trials of immune-oncology agents.

Wages NA, Chiuzan C, Panageas KS.

J Immunother Cancer. 2018 Aug 22;6(1):81. doi: 10.1186/s40425-018-0389-8.

27.

Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.

Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzales V, Abu-Akeel M, Merghoub T, Jones DR, Zhu XG, Arora A, Ariyan CE, Birsoy K, Wolchok JD, Panageas KS, Hollmann T, Bravo-Cordero JJ, White RM.

Cancer Discov. 2018 Aug;8(8):1006-1025. doi: 10.1158/2159-8290.CD-17-1371. Epub 2018 Jun 14.

28.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. Erratum in: Cancer Cell. 2018 Oct 8;34(4):691.

29.

Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.

Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS.

Ann Surg Oncol. 2018 Aug;25(8):2172-2177. doi: 10.1245/s10434-018-6370-4. Epub 2018 Feb 22.

30.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA.

Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

31.

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP.

Cancer Immunol Res. 2018 Feb;6(2):189-200. doi: 10.1158/2326-6066.CIR-17-0356. Epub 2018 Jan 16.

32.

Reply: Arterial Thromboembolism in Non-Hodgkin Lymphoma, as the Presentation of Occult Cancer, and With Cancer Therapies.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2018 Jan 16;71(2):260-262. doi: 10.1016/j.jacc.2017.10.088. No abstract available.

33.

The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS.

J Neurosurg. 2018 Nov 1;129(5):1231-1239. doi: 10.3171/2017.6.JNS17393.

34.

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.

Momtaz P, Harding JJ, Ariyan C, Coit DG, Merghoub T, Gasmi B, You D, Viale A, Panageas KS, Samoila A, Postow MA, Wolchok JD, Chapman PB.

Oncotarget. 2017 Sep 16;8(62):105000-105010. doi: 10.18632/oncotarget.21072. eCollection 2017 Dec 1.

35.

Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.

Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.

36.

Increased risk of arterial thromboembolism in older men with breast cancer.

Reiner AS, Navi BB, DeAngelis LM, Panageas KS.

Breast Cancer Res Treat. 2017 Dec;166(3):903-910. doi: 10.1007/s10549-017-4433-z. Epub 2017 Aug 23.

37.

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.

Kidwell KM, Postow MA, Panageas KS.

Clin Cancer Res. 2018 Feb 15;24(4):730-736. doi: 10.1158/1078-0432.CCR-17-1355. Epub 2017 Aug 23.

38.

Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI.

Neuro Oncol. 2017 Sep 1;19(9):1248-1254. doi: 10.1093/neuonc/nox066.

39.

Risk of Arterial Thromboembolism in Patients With Cancer.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2017 Aug 22;70(8):926-938. doi: 10.1016/j.jacc.2017.06.047.

40.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

41.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

42.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

43.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

44.

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C.

EBioMedicine. 2017 Apr;18:56-61. doi: 10.1016/j.ebiom.2017.03.029. Epub 2017 Mar 24.

45.

Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.

Davis JL, Langan RC, Panageas KS, Zheng J, Postow MA, Brady MS, Ariyan C, Coit DG.

Ann Surg Oncol. 2017 Jul;24(7):1989-1996. doi: 10.1245/s10434-017-5836-0. Epub 2017 Mar 16.

46.

Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.

Diamond EL, Panageas KS, Dallara A, Pollock A, Applebaum AJ, Carver AC, Pentsova E, DeAngelis LM, Prigerson HG.

J Pain Symptom Manage. 2017 Feb;53(2):257-264. doi: 10.1016/j.jpainsymman.2016.09.008. Epub 2016 Nov 1.

47.

Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.

Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, Chapman PB, Coit DG.

Ann Surg Oncol. 2017 Apr;24(4):939-946. doi: 10.1245/s10434-016-5642-0. Epub 2016 Nov 1.

48.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

49.

A peripheral blood biomarker estimates probability of survival: the neutrophil-lymphocyte ratio in noncancer patients.

Davis JL, Moutinho V Jr, Panageas KS, Coit DG.

Biomark Med. 2016 Sep;10(9):953-7. doi: 10.2217/bmm-2016-0103. Epub 2016 Aug 18.

50.

Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer.

Lipitz-Snyderman A, Sima CS, Atoria CL, Elkin EB, Anderson C, Blinder V, Tsai CJ, Panageas KS, Bach PB.

JAMA Intern Med. 2016 Oct 1;176(10):1541-1548. doi: 10.1001/jamainternmed.2016.4426.

Supplemental Content

Loading ...
Support Center